Concepedia

Author

Juliann Chmielecki

Foundation Medicine (United States)ORCID

Also Known As

Chmielecki, Juliann, J Chmielecki, J. Chmielecki, JACOB CHMIELECKI, Jacob Chmielecki, Jacob M. Chmielecki, Juliann Chmielecki, Juliann chmielecki, Kwiatkowski, David

381

Publications

17.4K

Citations

55

H-Index

65

Concepts

All Affiliations

Foundation Medicine (United States)Albany Medical Center HospitalAstraZeneca (United States)Memorial Sloan Kettering Cancer CenterAstraZeneca (United Kingdom)
JC

About

Juliann Chmielecki is an author at Foundation Medicine (United States) specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

32

3.9K

2

Health Sciences

9

9

384

3

Engineering

5

5

921

4

Biology

2

2

392

5

Natural Sciences

1

1

33

Juliann Chmielecki

×

84

Publications

15.8K

Citations

54

H-Index

YearCitations

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers, Caitlin Connelly, David Fabrizio,

Genome Medicine

2017

3.6K

Anchored multiplex PCR for targeted next-generation sequencing

Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova,

Nature Medicine

2014

898

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig,

Cancer Discovery

2015

782

Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors

Jack F. Shern, Li Chen, Juliann Chmielecki,

Cancer Discovery

2014

759

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima,

Clinical Cancer Research

2010

615

Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors

Juliann Chmielecki, Aimeé M. Crago, Mara Rosenberg,

Nature Genetics

2013

589

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Juliann Chmielecki, Jasmine Foo, Geoffrey R. Oxnard,

Science Translational Medicine

2011

524

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila,

Proceedings of the National Academy of Sciences

2012

434

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim,

Journal of Clinical Oncology

2019

379

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Suresh S. Ramalingam, Yi Cheng, C. Zhou,

Annals of Oncology

2018

352

Page 1